Phenprocoumon

Phenprocoumon

SCHEMBL43031

CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

VKORC1

The experimentally established mechanism targets of Phenprocoumon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
VKORC1 known ✓ Q9BQB6 3/20 0.73
CYP2C9 P11712 9/20 1.00
HSD17B10 Q99714 2/20 0.73
KDM4E B2RXH2 1/20 0.73
ALDH1A1 P00352 1/20 0.73
ALB P02768 1/20 0.73
PCSK7 Q16549 1/20 0.73
MEN1 O00255 1/20 0.73
KMT2A Q03164 1/20 0.73
NQO1 P15559 2/20 0.72
CYP3A4 P08684 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenprocoumon SCHEMBL24500477 1.00 CYP2C9 (1.00) CYP2C9VKORC1HSD17B10KDM4EALDH1A1
Phenprocoumon SCHEMBL29392123 1.00 CYP2C9 (1.00) CYP2C9VKORC1HSD17B10KDM4EALDH1A1
Phenprocoumon SCHEMBL24500472 1.00 CYP2C9 (1.00) CYP2C9VKORC1HSD17B10KDM4EALDH1A1
SCHEMBL7351110 0.93 CYP2C9 (0.87) CYP2C9VKORC1HSD17B10KDM4EALDH1A1
SCHEMBL8042698 0.92 CYP2C9 (0.86) CYP2C9VKORC1HSD17B10KDM4EALDH1A1
Warfarin SCHEMBL13724154 0.91 CYP2C9 (0.90) CYP2C9VKORC1HSD17B10KDM4EALDH1A1
SCHEMBL7406235 0.91 CYP2C9 (0.82) CYP2C9VKORC1HSD17B10KDM4EALDH1A1
SCHEMBL7350773 0.91 CYP2C9 (0.82) CYP2C9VKORC1HSD17B10KDM4EALDH1A1
SCHEMBL8868104 0.91 CYP2C9 (0.82) CYP2C9VKORC1HSD17B10KDM4EALDH1A1
SCHEMBL7348669 0.90 CYP2C9 (0.81) CYP2C9VKORC1HSD17B10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7480 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
EP-4651828-A1 DEVICE FOR ENDOVASCULAR DRUG DELIVERY AND USE THEREOF Julius-Maximilians-Universität Würzburg, in Vertretung des Freistaates Bayern (DE) 2025-11-26 EP claimed
US-20250333462-A1 PERIOSTIN COMPOUNDS FOR THE TREATMENT OF HAEMATOLOGICAL COMPLICATIONS CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS (DE) 2025-10-30 US claimed
US-20250326778-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2025-10-23 US claimed
EP-3938040-B1 VITAMIN K2 IN COMBINATION WITH ANTICOAGULANTS FOR USE IN TREATING MUSCLE SORENESS LESAFFRE & CIE (FR) 2025-05-21 EP claimed
EP-3823660-B1 PERIOSTIN COMPOUNDS FOR THE TREATMENT OF HAEMATOLOGICAL COMPLICATIONS UNIV DER JOHANNES GUTENBERG UNIV MAINZ (DE) 2025-05-07 EP claimed
US-12269021-B2 Artificial protein catalyst GLYTECH, INC. (JP) 2025-04-08 US claimed
US-20250034100-A1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIGEL PHARMACEUTICALS INC (US) 2025-01-30 US claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
WO-2024176961-A1 PROTEIN RECOGNIZING K-Ras GENE MUTATION CANCER 国立研究開発法人理化学研究所 2024-08-29 WO claimed
EP-0797424-A1 PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS WARNER-LAMBERT COMPANY (US) 1997-10-01 EP claimed
US-5629209-A Method and apparatus for detecting viscosity changes in fluids BRAUN BIOSYSTEMS, INC. 1997-05-13 US claimed
CN-1137748-A Gas used as local and subcutaneous transmission carrier and microspheres filled with gas precursor IMARX PHARMACEUTICAL CORP (US) 1996-12-11 CN claimed
EP-0740528-A1 GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION IMARX PHARMACEUTICAL CORP. (US) 1996-11-06 EP claimed
WO-1996018370-A1 PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS WARNER-LAMBERT COMPANY (US) 1996-06-20 WO claimed
EP-0682663-A1 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1995-11-22 EP claimed
WO-1995015118-A1 GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION IMARX PHARMACEUTICAL CORP. (US) 1995-06-08 WO claimed
WO-1994018188-A1 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS THE UPJOHN COMPANY (US) 1994-08-18 WO claimed
US-5077281-A Anticoagulants BIOLINK CORPORATION 1991-12-31 US claimed
US-4334020-A Method of producing L-glutamic acid by fermentation AJINOMOTO COMPANY INCORPORATED (JP) 1982-06-08 US claimed